Ligand Pharmaceuticals (FRA:LGDN) Float Percentage Of Total Shares Outstanding: 83.49% (As of Jul. 03, 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
73 GF Score
Price €266.00
GF Value €150.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Ligand Pharmaceuticals FRA:LGDN +1.53% 73 Float Percentage Of Total Shares Outstanding is 83.49% as of Jul. 03, 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 73/100 and a GF Value™ of €150.40 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ligand Pharmaceuticals's float shares is 16.73 Mil. Ligand Pharmaceuticals's total shares outstanding is 20.04 Mil. Ligand Pharmaceuticals's float percentage of total shares outstanding is 83.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ligand Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ligand Pharmaceuticals's Institutional Ownership is 90.47%.

FRA:LGDN
73GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ligand Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=16.73/20.04
=83.49%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 83.49% mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Float Percentage Of Total Shares Outstanding of 83.49% as of Jul. 03, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Ligand Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 83.49%. Overall, Ligand Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to DFTX and CGON?
Ligand Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 83.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 83.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.40, compared to a current price of €266.00 — trading 76.9% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 83.49%. Ligand Pharmaceuticals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Float Percentage Of Total Shares Outstanding is 83.49% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €266.00 is trading 76.9% above its estimated GF Value™ of €150.40. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Float Percentage Of Total Shares Outstanding: 83.49%
  • GF Value™: €150.40 vs. price of €266.00 (76.9% above fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
73GF Score

Get the complete analysis for FRA:LGDN

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€150.40
GF Value